53 citations,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
63 citations,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
April 2023 in “International Journal of Research in Dermatology” Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
2 citations,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
82 citations,
March 2016 in “Autoimmunity reviews” Animal models have helped understand hair loss from alopecia areata and find new treatments.
7 citations,
March 2017 in “Actas Dermo-Sifiliográficas” Several new treatments for different types of hair loss show promise in improving patient quality of life.
1 citations,
April 2018 in “Journal of Investigative Dermatology” Fzd2 is important for skin and hair development through various signaling ways.
2 citations,
March 2022 in “Journal of Personalized Medicine” Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.
6 citations,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
23 citations,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
11 citations,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
October 2020 in “Revista médica sinergía/Revista médica sinergia” Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
2 citations,
July 2023 in “JAAD Case Reports” A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.
8 citations,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
4 citations,
January 2023 in “Skin health and disease” Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
November 2024 in “Medicina” Recognizing scalp symptoms in PRP is crucial for proper diagnosis and treatment.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
2 citations,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
56 citations,
January 2019 in “Lancet” JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
45 citations,
April 2019 in “International Immunology” The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
2 citations,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
11 citations,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
9 citations,
July 2022 in “EMBO molecular medicine” Blocking certain immune signals can reduce skin damage from radiation therapy.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.